AMAM Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 0.64%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Ambrx Biopharma Share Price & Price History
Current Price: $28.00
Price Change: +0.30 (1.20%)
As of 03/7/2024 01:00 AM ET
Ambrx Biopharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/27/2023 | Daniel J. O'Connor | CEO | Sell | 50,012 | $9.82 | $491,117.84 | 342,845 |  |
| 10/27/2023 | Sonja Nelson | CFO | Sell | 12,778 | $9.82 | $125,479.96 | 130,079 | |
| 10/23/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 1,307,311 | $6.99 | $9,138,103.89 | 11,231,000 | |
| 9/18/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 751,233 | $9.24 | $6,941,392.92 | 69,465,823 | |
| 9/15/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 1,401,505 | $9.05 | $12,683,620.25 | 68,714,590 | |
| 4/19/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 135,850 | $11.15 | $1,514,727.50 | 9,485,714 | |
| 4/17/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 562,121 | $10.67 | $5,997,831.07 | 62,097,896 | |
| 4/13/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 1,193,808 | $9.16 | $10,935,281.28 | 60,693,808 | |
| 3/16/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 500,000 | $10.15 | $5,075,000.00 | 53,500,000 | |
| 3/14/2023 | Cormorant Asset Management, Lp | Major Shareholder | Buy | 250,000 | $9.95 | $2,487,500.00 | 52,750,000 | |
Ambrx Biopharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/26/2024 | Virtu Financial LLC | 20,386 | $0.29M | 0.0% | N/A | 0.032% |  |
| 2/26/2024 | Perceptive Advisors LLC | 78,811 | $1.12M | 0.0% | N/A | 0.125% | |
| 2/22/2024 | Sierra Summit Advisors LLC | 37,237 | $0.53M | 0.2% | N/A | 0.059% | |
| 2/15/2024 | Old Well Partners LLC | 14,400 | $0.21M | 0.2% | N/A | 0.023% | |
| 2/15/2024 | Parkman Healthcare Partners LLC | 87,678 | $1.25M | 0.2% | -41.5% | 0.139% | |
| 2/14/2024 | Altitude Crest Partners Inc. | 43,100 | $0.61M | 0.4% | N/A | 0.068% | |
| 2/14/2024 | Lighthouse Investment Partners LLC | 88,925 | $1.27M | 0.1% | N/A | 0.141% | |
| 2/13/2024 | Tower Research Capital LLC TRC | 5,614 | $80K | 0.0% | +2,288.9% | 0.009% | |
| 2/12/2024 | Monashee Investment Management LLC | 207,500 | $2.96M | 0.5% | +196.4% | 0.329% | |
| 2/12/2024 | TD Asset Management Inc | 140,256 | $2M | 0.0% | +27.0% | 0.222% | |
| 2/6/2024 | WuXi AppTec Co. Ltd. | 1,000,000 | $14.24M | 36.9% | N/A | 1.584% | |
| 1/31/2024 | Federated Hermes Inc. | 330,949 | $4.71M | 0.0% | -86.2% | 0.524% | |
| 1/30/2024 | HealthInvest Partners AB | 57,847 | $0.82M | 0.7% | N/A | 0.092% | |
| 1/24/2024 | China Universal Asset Management Co. Ltd. | 7,303 | $0.10M | 0.0% | N/A | 0.012% | |
| 11/15/2023 | Alps Advisors Inc. | 45,531 | $0.52M | 0.0% | +12.2% | 0.073% | |
| 11/14/2023 | Monashee Investment Management LLC | 70,000 | $0.81M | 0.3% | N/A | 0.113% | |
| 11/13/2023 | Federated Hermes Inc. | 2,395,867 | $27.55M | 0.1% | N/A | 3.864% | |
| 11/13/2023 | NWI Management LP | 160,935 | $1.85M | 0.1% | N/A | 0.260% | |
| 11/13/2023 | FMR LLC | 1,761,058 | $20.25M | 0.0% | -20.3% | 2.840% | |
| 11/9/2023 | Innovis Asset Management LLC | 31,137 | $0.36M | 0.1% | +85.1% | 0.050% | |
| 10/27/2023 | TD Asset Management Inc | 110,456 | $1.27M | 0.0% | +73.3% | 0.178% | |
| 10/24/2023 | Bank of New York Mellon Corp | 47,433 | $0.55M | 0.0% | N/A | 0.076% | |
| 8/15/2023 | Silverarc Capital Management LLC | 100,000 | $1.65M | 0.5% | N/A | 0.162% | |
| 8/15/2023 | HighVista Strategies LLC | 153,431 | $2.53M | 1.2% | N/A | 0.248% | |
| 8/15/2023 | Commodore Capital LP | 3,175,000 | $52.26M | 5.9% | -33.9% | 5.142% | |
| 8/14/2023 | Cormorant Asset Management LP | 9,616,155 | $158.28M | 8.9% | +13.1% | 15.573% | |
| 8/11/2023 | VR Adviser LLC | 2,484,960 | $40.90M | 6.5% | -24.7% | 4.499% | |
| 8/11/2023 | ExodusPoint Capital Management LP | 477,558 | $7.86M | 0.1% | +2,349.4% | 0.865% | |
| 8/9/2023 | TD Asset Management Inc | 63,728 | $1.05M | 0.0% | +358.5% | 0.115% | |
| 8/3/2023 | Innovis Asset Management LLC | 16,826 | $0.28M | 0.1% | N/A | 0.030% | |
| 7/20/2023 | Exchange Traded Concepts LLC | 9,830 | $0.16M | 0.0% | N/A | 0.018% | |
| 7/13/2023 | QP Wealth Management LLC | 12,670 | $0.21M | 0.3% | N/A | 0.023% | |
| 5/15/2023 | Commodore Capital LP | 4,803,447 | $42.85M | 6.5% | N/A | 12.433% | |
| 5/15/2023 | Ghost Tree Capital LLC | 250,000 | $2.23M | 0.7% | N/A | 0.647% | |
| 5/15/2023 | Farallon Capital Management LLC | 361,000 | $3.22M | 0.0% | N/A | 0.934% | |
| 5/10/2023 | Tocqueville Asset Management L.P. | 12,500 | $0.11M | 0.0% | N/A | 0.032% | |
| 5/9/2023 | Tower Research Capital LLC TRC | 20,440 | $0.18M | 0.0% | +681,233.3% | 0.053% | |
| 4/28/2023 | Fosun International Ltd | 249,190 | $2.22M | 0.2% | -87.1% | 0.645% | |
| 3/15/2023 | B. Riley Wealth Advisors Inc. | 20,000 | $45K | 0.0% | N/A | 0.052% | |
| 2/14/2023 | Alpine Global Management LLC | 46,723 | $0.11M | 0.0% | N/A | 0.121% | |
| 11/14/2022 | Cormorant Asset Management LP | 2,336,389 | $2.52M | 0.2% | -6.0% | 6.050% | |
| 5/16/2022 | Suvretta Capital Management LLC | 1,491,832 | $6.15M | 0.2% | +41.0% | 3.866% | |
| 2/15/2022 | Adage Capital Partners GP L.L.C. | 1,923,700 | $17.37M | 0.0% | +5.3% | 5.107% | |
| 2/14/2022 | Suvretta Capital Management LLC | 1,057,735 | $9.55M | 0.2% | N/A | 2.808% | |
| 11/15/2021 | Tudor Investment Corp Et Al | 20,143 | $0.27M | 0.0% | -66.4% | 0.053% | |
| 11/12/2021 | Ghisallo Capital Management LLC | 15,000 | $0.20M | 0.0% | -62.5% | 0.040% | |
| 11/9/2021 | BlackRock Inc. | 820,221 | $11.07M | 0.0% | -3.6% | 2.177% | |
Data available starting January 2016
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Read More on Ambrx Biopharma
Today's Range
Now: $28.00
52 Week Range
Now: $28.00
Volume
N/A
Average Volume
2,123,967 shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
